The Philadelphia Business Journal reported on December 8th that West Conshohocken-based Madrigal Pharmaceuticals is relocating its headquarters to a larger space in West Conshohocken. Madrigal has made its home at Four Tower Bridge and is moving to the nearby Keystone Development + Investment’s 1K1 building.

Madrigal is widely recognized for its research and obtaining the first U.S. Food and Drug Administration-approved treatment for MASH, a serious liver disease.

From the article:

Madrigal (NASDAQ: MDGL), which generated more than $600 million in sales during the first three quarters of 2025, has leased 54,000-square-foot for its headquarters at the roughly 254,000-square-foot Four Falls Corporate Center building. The space is 86% larger than the 29,000 square feet it has been leasing at Four Tower Bridge, where it has about 200 workers.

The move is expected to be completed by mid-2026. You can read the full article here.

Photo: Keystone Development + Investment